Medical Gas Supply in East Africa: The Invisible Infrastructure Behind Every Operating Theatre and ICU Bed
- The Gas That Keeps Patients Alive and the Supply Chain That Nearly Collapsed
- Florence Nakamya and the Expansion Loan That Data Could Unlock
- Production Technology Tiers and Their Investment Implications
- Cylinder Logistics and the Asset Management Challenge
- Demand Forecasting and the Hospital Procurement Cycle
- The Investment Thesis for Regional Medical Gas Infrastructure
The COVID-19 pandemic exposed a catastrophic gap in East African medical gas infrastructure when hospitals across Kenya, Tanzania, Uganda, and Ethiopia simultaneously discovered that their oxygen supply chains could not scale beyond baseline demand, contributing to excess mortality that health ministries are still quantifying three years later, and yet the structural investment required to prevent a recurrence remains largely unmade because the 40 to 50 medical gas suppliers operating across the region lack the production analytics, distribution logistics data, and customer demand forecasting capabilities needed to attract the USD 180 million to USD 260 million in capital investment that industry analysts estimate is required to bring regional medical gas capacity to levels that can serve both routine clinical demand and pandemic surge requirements. Florence Nakamya, who operates a pressure swing adsorption oxygen generation plant in Kampala supplying medical-grade oxygen to 32 hospitals and clinics across central Uganda, generates UGX 890 million in annual revenue but cannot secure the UGX 4.2 billion expansion loan she needs because her financial records do not disaggregate revenue by customer segment, her production data does not demonstrate capacity utilization trends, and her distribution cost analysis does not exist in a format that any commercial lender would accept as a basis for credit evaluation. AskBiz gives medical gas suppliers the production monitoring, distribution analytics, and investor-ready financial reporting that unlock the growth capital this critical healthcare infrastructure sector desperately needs.
- The Gas That Keeps Patients Alive and the Supply Chain That Nearly Collapsed
- Florence Nakamya and the Expansion Loan That Data Could Unlock
- Production Technology Tiers and Their Investment Implications
- Cylinder Logistics and the Asset Management Challenge
- Demand Forecasting and the Hospital Procurement Cycle
The Gas That Keeps Patients Alive and the Supply Chain That Nearly Collapsed#
Medical oxygen is classified by the World Health Organization as an essential medicine, yet it remains one of the most chronically undersupplied healthcare inputs in sub-Saharan Africa. Before the COVID-19 pandemic, an estimated 50 percent of healthcare facilities in East Africa lacked reliable access to medical-grade oxygen, contributing to preventable mortality from pneumonia, surgical complications, obstetric emergencies, and neonatal respiratory distress that collectively account for over 300,000 deaths annually across the region. The pandemic transformed medical oxygen from a background clinical input into a front-page crisis when hospitalised COVID-19 patients with severe respiratory symptoms required continuous oxygen therapy at flow rates of 10 to 60 litres per minute, overwhelming supply infrastructure designed for routine surgical and emergency use. Kenya estimated pre-pandemic medical oxygen demand at approximately 2,800 tonnes annually, served by a combination of large-scale cryogenic production plants operated by multinational industrial gas companies and smaller pressure swing adsorption plants operated by local companies. Pandemic peak demand exceeded 8,500 tonnes annualized, a three-fold increase that the existing supply chain could not accommodate, leading to oxygen rationing at hospitals, patient transfers between facilities based on oxygen availability rather than clinical need, and documented cases of patient deaths directly attributable to oxygen shortage. Tanzania experienced similar dynamics with pre-pandemic demand of approximately 2,200 tonnes against pandemic peak requirements exceeding 6,000 tonnes. Uganda pre-pandemic consumption of approximately 1,800 tonnes surged past 4,500 tonnes. Ethiopia, with the largest population in the region at approximately 126 million, faced the most severe absolute shortfall with pre-pandemic supply of roughly 3,200 tonnes against pandemic demand exceeding 9,000 tonnes. Post-pandemic, medical oxygen demand has settled at levels approximately 40 to 60 percent above pre-pandemic baselines as hospitals maintain higher oxygen reserves, expand ICU capacity, and adopt oxygen therapy protocols for conditions previously managed without supplemental oxygen. This elevated baseline creates sustained demand growth that makes medical gas supply one of the most compelling healthcare infrastructure investment opportunities in the region. The total addressable market for medical gases in East Africa, including oxygen, nitrous oxide, medical air, carbon dioxide for insufflation, and anaesthetic gases, is estimated at USD 120 million to USD 165 million annually and growing at 12 to 18 percent driven by hospital expansion, surgical volume growth, and improved clinical protocols.
Florence Nakamya and the Expansion Loan That Data Could Unlock#
Florence Nakamya trained as a biomedical engineer at Makerere University before spending six years maintaining medical equipment at Mulago National Referral Hospital, where she observed firsthand the oxygen supply disruptions that forced clinicians to ration a medicine that should be as available as running water. In 2020, she invested UGX 1.2 billion of personal savings and family contributions to purchase a 30-cubic-metre-per-hour pressure swing adsorption oxygen generation system manufactured in China, install it in a purpose-built facility in the Kampala industrial area, and obtain the National Drug Authority manufacturing license required to produce and distribute medical-grade oxygen in Uganda. Her PSA plant separates oxygen from ambient air using zeolite molecular sieves that adsorb nitrogen under pressure, producing oxygen at 93 to 95 percent concentration that meets the pharmacopoeia specification for medical-grade oxygen. The system operates continuously and produces approximately 650 cylinders of medical oxygen per day when running at full capacity, with each cylinder containing 6.8 cubic metres of oxygen at 150 bar pressure. Florence current customer base comprises 32 hospitals and clinics across central Uganda including 8 private hospitals in Kampala, 12 district health centres within 120 kilometres of the capital, 6 private clinics, 4 maternity homes, and 2 veterinary facilities. Monthly revenue averages UGX 74 million from oxygen sales at an average price of UGX 35,000 per cylinder for E-size cylinders and UGX 85,000 for larger H-size cylinders, plus UGX 12 million from cylinder rental fees charged to customers who do not own their own cylinders. Annual revenue of UGX 890 million generates a gross margin she estimates at approximately 38 percent, though this estimate is imprecise because she does not track production costs, distribution costs, and cylinder management costs as separate categories. Her expansion plan calls for adding a second PSA unit with 50 cubic metres per hour capacity, a bulk liquid oxygen storage and filling system to serve larger hospitals with piped oxygen installations, and three additional delivery vehicles to extend distribution reach into eastern Uganda. Total capital requirement is UGX 4.2 billion. She has approached four commercial banks in Kampala, all of which have requested financial projections, demand analysis, and operational performance data that she cannot produce from her current record-keeping system. Her production records consist of daily meter readings noting total oxygen output and number of cylinders filled. Her sales records are invoices filed chronologically without aggregation by customer, product type, or period. Her distribution costs are embedded in general operating expenses without route-level or customer-level attribution. The banks have not questioned the market opportunity, which is evident to anyone who witnessed the pandemic oxygen crisis. They have questioned Florence ability to demonstrate that her current operation is financially sound and that expansion projections are grounded in verifiable operational data rather than optimistic assumptions.
Production Technology Tiers and Their Investment Implications#
Medical gas production in East Africa operates across three distinct technology tiers with different capital requirements, operating economics, and market positioning. Understanding these tiers is essential for investors evaluating entry points into the sector. The first tier comprises pressure swing adsorption systems like Florence operation that generate oxygen on-site from ambient air. PSA systems range from small units producing 5 cubic metres per hour suitable for individual hospital installations costing USD 25,000 to USD 60,000, to medium systems producing 20 to 50 cubic metres per hour for commercial cylinder filling operations costing USD 150,000 to USD 400,000, to large systems producing 100 to 200 cubic metres per hour for regional supply hubs costing USD 600,000 to USD 1.5 million. PSA technology advantages include lower capital cost relative to cryogenic plants, simpler operation requiring technician-level rather than engineer-level staffing, and independence from liquid oxygen supply chains. Disadvantages include oxygen purity limited to 93 to 95 percent compared to 99.5 percent from cryogenic distillation, higher per-unit production cost at scale, and inability to produce liquid oxygen for piped hospital installations. The second tier comprises cryogenic air separation units that cool air to minus 183 degrees Celsius to liquefy and distill oxygen, nitrogen, and argon. Cryogenic plants produce oxygen at 99.5 percent purity in both gaseous and liquid form, with production capacities ranging from 50 to 500 tonnes per day. Capital investment for a cryogenic plant ranges from USD 3 million to USD 15 million depending on capacity, making this technology accessible only to well-capitalized industrial gas companies. Two multinational industrial gas companies operate cryogenic plants in Kenya and one in Tanzania, collectively producing approximately 60 percent of the region medical-grade oxygen. These plants also produce industrial-grade oxygen, nitrogen, and argon, with medical oxygen typically representing 15 to 30 percent of total output by volume but commanding a price premium of 40 to 80 percent over industrial grades due to pharmacopoeia compliance, quality testing, and regulatory requirements. The third tier comprises oxygen concentrators, small electrical devices that produce low-flow oxygen at 1 to 10 litres per minute for individual patient use. Concentrators costing USD 400 to USD 2,000 each are appropriate for home care and small clinic use but cannot fill cylinders or supply piped oxygen systems. Post-pandemic procurement programmes have distributed over 45,000 concentrators across East African healthcare facilities, creating a large installed base that requires maintenance and eventual replacement. For investors, the most attractive entry point is the medium-scale PSA tier serving as a regional cylinder supply hub with 30 to 100 cubic metres per hour capacity, bridging the gap between the multinational cryogenic operators who focus on large urban hospitals and the facility-level concentrators that cannot serve the growing mid-market of district hospitals and private clinics requiring 20 to 100 cylinders per month.
Data-backed guides on AI, eCommerce, and SME strategy — straight to your inbox.
Cylinder Logistics and the Asset Management Challenge#
Medical gas cylinders are high-value steel or aluminium pressure vessels that cost USD 120 to USD 350 each depending on size and material, require hydrostatic pressure testing every five years at a cost of USD 15 to USD 25 per cylinder, and have useful lives of 20 to 30 years if properly maintained. A medical gas supplier like Florence maintains an active cylinder fleet of approximately 3,200 cylinders valued at roughly UGX 1.4 billion representing her single largest capital asset after the PSA plant itself. Cylinder management is the operational function that most directly determines profitability in the medical gas distribution business because cylinders that are not circulating are not generating revenue. In Tanzania, equivalent E-size cylinders cost TZS 65,000 to TZS 85,000 each, while Ethiopian suppliers price H-size cylinders at ETB 18,000 to ETB 28,000 depending on the manufacturer. A cylinder sitting empty at a hospital for three weeks because the facility has not called for a refill exchange represents lost production capacity and tied-up capital. A cylinder that has been delivered to a customer and not returned for 90 days may be lost, damaged, or in use as a door prop in a facility that has forgotten it is a rented asset. Florence estimates that approximately 380 of her 3,200 cylinders, roughly 12 percent of the fleet, are in unknown status at any time, meaning she does not know their physical location, fill status, or condition. At an average replacement cost of UGX 430,000 per cylinder, the capital at risk in untracked cylinders is UGX 163 million. Annual cylinder losses from unreturned, stolen, or damaged cylinders average 85 units costing UGX 36.5 million in replacement capital that directly erodes profitability. The cylinder tracking challenge is compounded by the absence of a standardized cylinder identification system across the East African medical gas industry. Florence cylinders are painted in her company colours and stamped with serial numbers, but hospitals that receive cylinders from multiple suppliers often commingle them, returning competitor cylinders to Florence drivers and vice versa. Cross-contamination of cylinder fleets creates reconciliation disputes between gas suppliers that consume management time and occasionally escalate into commercial conflicts. Investors evaluating medical gas businesses must scrutinize cylinder fleet management as a key operational metric. A supplier with a cylinder turnover ratio of 4.5 times per month, meaning each cylinder completes 4.5 fill-deliver-return cycles monthly, generates 50 percent more revenue from the same fleet size than a supplier with a turnover ratio of 3.0. Improving cylinder turnover from 3.0 to 4.5 through better tracking and customer management is equivalent to purchasing 50 percent more cylinders without the capital expenditure, making cylinder management efficiency one of the highest-return operational improvements available to medical gas businesses.
Demand Forecasting and the Hospital Procurement Cycle#
Medical gas demand at the hospital level follows patterns that are partially predictable from clinical activity data but that most gas suppliers do not analyse because they lack the customer-level consumption data to build forecasting models. A hospital surgical schedule directly drives oxygen consumption because general anaesthesia typically requires 2 to 4 litres per minute of oxygen flow through the anaesthesia machine for the duration of surgery, plus post-operative oxygen therapy at 2 to 6 litres per minute for recovery periods ranging from 30 minutes to 24 hours depending on the procedure. A hospital performing 15 surgical procedures daily consumes approximately 8 to 12 E-size cylinders of oxygen for surgical and post-operative use alone. Emergency department oxygen consumption varies with trauma volume, which correlates with seasonal patterns including increased road traffic accidents during holiday periods and increased respiratory presentations during cold and rainy seasons. Maternity oxygen consumption correlates with delivery volumes and caesarean section rates. ICU consumption is the most variable and least predictable category, driven by individual patient acuity levels that can change daily. Florence 32 customers exhibit demand patterns that range from highly stable to extremely volatile. Her most predictable customer, a private surgical hospital performing an average of 22 elective procedures daily, orders 45 E-size cylinders weekly with a coefficient of variation below 8 percent. Her least predictable customer, a district health centre that serves as a primary trauma receiving facility, orders between 12 and 38 cylinders weekly depending on trauma volume that is influenced by market days, local events, and road conditions. Without customer-level demand data, Florence manages her production schedule and distribution logistics based on aggregate weekly patterns rather than customer-specific forecasting. She runs her PSA plant at a steady output rate and fills cylinders into inventory that she distributes based on customer calls requesting refills. This reactive model means she maintains a buffer inventory of approximately 400 filled cylinders worth UGX 14 million in tied-up working capital to ensure she can respond to unexpected demand spikes. With customer-level demand forecasting based on historical consumption patterns, seasonal adjustments, and known schedule changes such as a hospital adding a second operating theatre, she could reduce buffer inventory by an estimated 35 to 45 percent while improving fill rates and delivery responsiveness. AskBiz provides the customer analytics infrastructure that transforms reactive order fulfillment into proactive demand management, with the Customer Management module tracking each hospital consumption history, ordering patterns, and relationship health metrics that enable Florence to anticipate needs rather than simply respond to calls.
The Investment Thesis for Regional Medical Gas Infrastructure#
Medical gas supply in East Africa presents an investment thesis built on three converging factors that create a multi-year growth opportunity with defensible competitive positioning. First, baseline demand growth of 12 to 18 percent annually driven by hospital bed expansion, increasing surgical volumes, and clinical protocol improvements that prescribe oxygen therapy for conditions previously managed without supplemental oxygen. Kenya plans to add approximately 12,000 hospital beds through county government and private sector investment by 2030. Tanzania Health Sector Strategic Plan targets 8,000 additional beds. Uganda National Health Infrastructure Master Plan projects 6,500 new beds. Each bed generates average medical oxygen demand of 0.8 to 1.5 cylinders per month, adding 21,200 to 39,750 cylinders of monthly demand across the region. Second, import substitution opportunity as locally produced PSA oxygen displaces imported liquid oxygen that currently supplies approximately 40 percent of the Kenyan market and 25 percent of the Tanzanian market through multinational industrial gas companies that produce in South Africa and ship via road tanker at costs that include 2,000 to 3,500 kilometres of transport. Local PSA production achieves cost-per-cylinder economics 30 to 45 percent below imported liquid oxygen at current fuel prices, creating a structural cost advantage that protects local producers against multinational competition. Third, regulatory tailwinds as national pharmaceutical regulators strengthen enforcement of medical gas quality standards that favour licensed producers over informal refilling operations that currently serve an estimated 20 to 30 percent of the market without proper quality testing or documentation. The National Drug Authority in Uganda has increased inspections of medical gas facilities and issued closure orders against 14 unlicensed filling operations in the past 18 months, redirecting their customer base to licensed producers like Florence. For an investor providing the UGX 4.2 billion Florence needs for expansion, the financial model projects revenue growth from UGX 890 million to UGX 2.4 billion within 30 months as the additional PSA capacity and expanded distribution reach capture market share from both informal competitors and the underserved district hospital segment. At projected net margins of 22 to 28 percent post-expansion, the investment generates annual returns exceeding UGX 530 million against total capital deployed of UGX 5.4 billion including existing assets, implying a return on capital of approximately 10 percent in the first full year scaling to 18 percent by year three as volume growth absorbs fixed costs. AskBiz provides the operational data infrastructure that makes this investment case credible, generating the production reports, customer analytics, and financial projections that transform Florence promising but undocumented business into an investable proposition that commercial lenders and equity investors can evaluate with confidence.
Our team combines expertise in data analytics, SME strategy, and AI tools to produce practical guides that help founders and operators make better business decisions.
Ready to make smarter decisions?
AskBiz turns your business data into actionable intelligence — no spreadsheets, no consultants.
Start free — no credit card required →